Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | IP6K1 | Q92551 | 6/20 | 0.49 |
| ▸ | IP6K3 | Q96PC2 | 3/20 | 0.49 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.49 |
| ▸ | PARP1 | P09874 | 9/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.45 |
| ▸ | PIM1 | P11309 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27576841 | 0.89 | PARP1 (0.49) | ROCK2IP6K1IP6K3IP6K2PARP1 | |
| SCHEMBL12304875 | 0.81 | PARP1 (0.53) | ROCK2IP6K1IP6K3IP6K2PARP1 | |
| SCHEMBL496967 | 0.78 | IP6K1 (0.65) | IP6K1IP6K3IP6K2PARP1SLC2A1 | |
| SCHEMBL12332880 | 0.75 | PARP1 (0.46) | ROCK2IP6K1IP6K3IP6K2PARP1 | |
| SCHEMBL12304877 | 0.74 | PARP1 (0.53) | IP6K1IP6K3IP6K2PARP1SLC2A1 | |
| SCHEMBL12788028 | 0.74 | PARP1 (0.53) | IP6K1IP6K3IP6K2PARP1SLC2A1 | |
| SCHEMBL12304872 | 0.73 | PARP1 (0.51) | IP6K1IP6K3IP6K2PARP1SLC2A1 | |
| SCHEMBL12788049 | 0.73 | PARP1 (0.51) | IP6K1IP6K3IP6K2PARP1SLC2A1 | |
| SCHEMBL27848525 | 0.73 | BCL2 (0.48) | ROCK2IP6K1PARP1SLC2A1PIM1 | |
| SCHEMBL28794202 | 0.72 | PARP1 (0.54) | IP6K1PARP1PIM1RPS6KA3PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012028861-A1 | PURE ERLOTINIB | GENERICS [UK] LIMITED (GB) | 2012-03-08 | — | — | WO | disclosed |
| US-7960545-B2 | Process for the prepartion of erlotinib | NATCO PHARMA LIMITED (IN) | 2011-06-14 | — | — | US | disclosed |
| US-20090306377-A1 | NOVEL PROCESS FOR THE PREPARTION OF ERLOTINIB | NATCO PHARMA LIMITED (IN) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306377-A1 | NOVEL PROCESS FOR THE PREPARTION OF ERLOTINIB | ERBB4, ABL1, KRAS | ROCK2 2123/4885IP6K1 1335/4885IP6K3 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.